{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T20:50:16Z","timestamp":1761598216331},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2020,6,4]],"date-time":"2020-06-04T00:00:00Z","timestamp":1591228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,4]],"date-time":"2020-06-04T00:00:00Z","timestamp":1591228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologe"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1007\/s00120-020-01235-4","type":"journal-article","created":{"date-parts":[[2020,6,4]],"date-time":"2020-06-04T13:03:41Z","timestamp":1591275821000},"page":"797-803","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Die Erstlinientherapie des metastasierten Urothelkarzinoms"],"prefix":"10.1007","volume":"59","author":[{"given":"A.","family":"Zacharis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Gr\u00fcllich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,6,4]]},"reference":[{"key":"1235_CR1","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1038\/s41585-019-0245-8","volume":"16","author":"AB Apolo","year":"2019","unstructured":"Apolo\u00a0AB (2019) Determining superior first-line therapy in metastatic bladder cancer. Nat Rev Urol 16:698\u2013699","journal-title":"Nat Rev Urol"},{"issue":"4","key":"1235_CR2","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/sj.bjc.6602378","volume":"92","author":"A Ardavanis","year":"2005","unstructured":"Ardavanis\u00a0A, Tryfonopoulos\u00a0D, Alexopoulos\u00a0A, Kandylis\u00a0C, Lainakis\u00a0G, Rigatos\u00a0G (2005) Gemcitabine and docetaxel as first-line treatment for advanced urothelial carcinoma: a\u00a0phase II study. Br J Cancer 92(4):645","journal-title":"Br J Cancer"},{"issue":"10","key":"1235_CR3","doi-asserted-by":"publisher","first-page":"3173","DOI":"10.1200\/JCO.1999.17.10.3173","volume":"17","author":"DF Bajorin","year":"1999","unstructured":"Bajorin\u00a0DF et al (1999) Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J\u00a0Clin Oncol 17(10):3173\u20133181","journal-title":"J Clin Oncol"},{"issue":"11","key":"1235_CR4","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1016\/S1470-2045(17)30616-2","volume":"18","author":"AV Balar","year":"2017","unstructured":"Balar\u00a0AV, Castellano\u00a0D, O\u2019Donnell\u00a0PH, Grivas\u00a0P, Vuky\u00a0J, Powles\u00a0T, Plimack\u00a0ER, Hahn\u00a0NM, de Wit\u00a0R, Pang\u00a0L, Savage\u00a0MJ, Perini\u00a0RF, Keefe\u00a0SM, Bajorin\u00a0D, Bellmunt\u00a0J (2017) First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a\u00a0multicentre, single-arm, phase 2 study. Lancet Oncol 18(11):1483","journal-title":"Lancet Oncol"},{"issue":"10064","key":"1235_CR5","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","volume":"389","author":"AV Balar","year":"2017","unstructured":"Balar\u00a0AV, Galsky\u00a0MD, Rosenberg\u00a0JE, Powles\u00a0T, Petrylak\u00a0DP, Bellmunt\u00a0J, Loriot\u00a0Y, Necchi\u00a0A, Hoffman-Censits\u00a0J, Perez-Gracia\u00a0JL, Dawson\u00a0NA, van der Heijden\u00a0MS, Dreicer\u00a0R, Srinivas\u00a0S, Retz\u00a0MM, Joseph\u00a0RW, Drakaki\u00a0A, Vaishampayan\u00a0UN, Sridhar\u00a0SS, Quinn\u00a0DI, Dur\u00e1n\u00a0I, Shaffer\u00a0DR, Eigl\u00a0BJ, Grivas\u00a0PD, Yu\u00a0EY, Li\u00a0S, Kadel\u00a0EE 3rd, Boyd\u00a0Z, Bourgon\u00a0R, Hegde\u00a0PS, Mariathasan\u00a0S, Th\u00e5str\u00f6m\u00a0A, Abidoye\u00a0OO, Fine\u00a0GD, Bajorin\u00a0DF, IMvigor210 Study Group. (2017) Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a\u00a0single-arm, multicentre, phase 2 trial. Lancet 389(10064):67","journal-title":"Lancet"},{"key":"1235_CR6","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1200\/JCO.2011.38.6979","volume":"30","author":"J Bellmunt","year":"2012","unstructured":"Bellmunt\u00a0J, von der Maase\u00a0H, Mead\u00a0GM, Skoneczna\u00a0I, De Santis\u00a0M, Daugaard\u00a0G, Boehle\u00a0A, Chevreau\u00a0C, Paz-Ares\u00a0L, Laufman\u00a0LR, Winquist\u00a0E, Raghavan\u00a0D, Marreaud\u00a0S, Collette\u00a0S, Sylvester\u00a0R, de Wit\u00a0R (2012) Randomized phase III study comparing paclitaxel\/cisplatin\/gemcitabine and gemcitabine\/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J\u00a0Clin Oncol 30:1107\u20131113","journal-title":"J Clin Oncol"},{"issue":"12","key":"1235_CR7","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.1002\/cncr.24313","volume":"115","author":"F Calabr\u00f2","year":"2009","unstructured":"Calabr\u00f2\u00a0F, Lorusso\u00a0V, Rosati\u00a0G, Manzione\u00a0L, Frassineti\u00a0L, Sava\u00a0T, Di Paula\u00a0ED, Alonso\u00a0S, Sternberg\u00a0CN (2009) Gemcitabine and paclitaxel every 2\u00a0weeks in patients with previously untreated urothelial carcinoma. Cancer 115(12):2652","journal-title":"Cancer"},{"issue":"2","key":"1235_CR8","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1200\/JCO.2011.37.3571","volume":"30","author":"M De Santis","year":"2012","unstructured":"De Santis\u00a0M, Bellmunt\u00a0J, Mead\u00a0G, Kerst\u00a0JM, Leahy\u00a0M, Maroto\u00a0P, Gil\u00a0T, Marreaud\u00a0S, Daugaard\u00a0G, Skoneczna\u00a0I, Collette\u00a0S, Lorent\u00a0J, de Wit\u00a0R, Sylvester\u00a0R (2012) Randomized phase II\/III trial assessing gemcitabine\/carboplatin and methotrexate\/carboplatin\/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J\u00a0Clin Oncol 30(2):191\u2013199","journal-title":"J Clin Oncol"},{"key":"1235_CR9","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1200\/EDBK_201193","volume":"38","author":"B Dietrich","year":"2018","unstructured":"Dietrich\u00a0B, Siefker-Radtke\u00a0AO, Srinivas\u00a0S, Yu\u00a0EY (2018) Systemic therapy for advanced urothelial carcinoma: current standards and treatment considerations. Am Soc Clin Oncol Educ Book 38:342\u2013353","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"1235_CR10","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.eururo.2006.12.029","volume":"52","author":"L Dogliotti","year":"2007","unstructured":"Dogliotti\u00a0L et al (2007) Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a\u00a0randomized phase 2 trial. Eur Urol 52:134\u2013141","journal-title":"Eur Urol"},{"key":"1235_CR11","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.eururo.2019.07.032","volume":"76","author":"E Feld","year":"2019","unstructured":"Feld\u00a0E et al (2019) Effectiveness of first-line immune checkpoint blockade versus carboplatin-based chemotherapy for metastatic urothelial cancer. Eur Urol 76:524\u2013532","journal-title":"Eur Urol"},{"key":"1235_CR12","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/j.ejca.2012.12.027","volume":"49","author":"J Ferlay","year":"2013","unstructured":"Ferlay\u00a0J et\u00a0al (2013) Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 49:1374","journal-title":"Eur J Cancer"},{"key":"1235_CR13","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1093\/annonc\/mdr156","volume":"23","author":"MD Galsky","year":"2012","unstructured":"Galsky\u00a0MD et al (2012) Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma. Ann Oncol 23:406","journal-title":"Ann Oncol"},{"issue":"3","key":"1235_CR14","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/S1470-2045(10)70275-8","volume":"12","author":"MD Galsky","year":"2011","unstructured":"Galsky\u00a0MD, Hahn\u00a0NM, Rosenberg\u00a0J, Sonpavde\u00a0G, Hutson\u00a0T, Oh\u00a0WK, Dreicer\u00a0R, Vogelzang\u00a0N, Sternberg\u00a0C, Bajorin\u00a0DF, Bellmunt\u00a0J (2011) A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol 12(3):211","journal-title":"Lancet Oncol"},{"key":"1235_CR15","volume-title":"Atlas der Krebsinzidenz und -mortalit\u00e4t in Deutschland (GEKID-Atlas)","author":"Gesellschaft der epidemiologischen Krebsregister in Deutschland e.\u202fV.","year":"2020","unstructured":"Gesellschaft der epidemiologischen Krebsregister in Deutschland e.\u202fV. (2020) Atlas der Krebsinzidenz und -mortalit\u00e4t in Deutschland (GEKID-Atlas)"},{"issue":"5","key":"1235_CR16","doi-asserted-by":"publisher","first-page":"v851","DOI":"10.1093\/annonc\/mdz394","volume":"30","author":"E Grande","year":"2019","unstructured":"Grande\u00a0E, Galsky\u00a0M, Arranz Arija\u00a0JA, De Santis\u00a0M, Davis\u00a0ID, De Giorgi\u00a0UFF, Mencinger\u00a0M, Kikuchi\u00a0E, Garcia del Muro\u00a0X, Gumus\u00a0M, \u00d6zg\u00fcro\u011flu\u00a0M, Rezazadeh Kalebasty\u00a0A, Park\u00a0SH, Alekseev\u00a0BY, Schutz\u00a0FAB, Li\u00a0J, Mecke\u00a0A, Mariathasan\u00a0S, Thastrom\u00a0A, Bamias\u00a0A (2019) IMvigor130: efficacy and safety from a\u00a0phase 3 study of atezolizumab (atezo) as monotherapy or combined with platinum-based chemotherapy (PBC) vs placebo + PBC in previously untreated locally advanced or metastatic urothelial carcinoma (mUC). Ann Oncol 30(5):v851\u2013v934. https:\/\/doi.org\/10.1093\/annonc\/mdz394","journal-title":"Ann Oncol"},{"issue":"5","key":"1235_CR17","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1038\/sj.bjc.6602112","volume":"91","author":"SA Hussain","year":"2004","unstructured":"Hussain\u00a0SA et al (2004) A phase I\/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a\u00a021-day schedule in patients with advanced and metastatic bladder cancer. Br J Cancer 91(5):844\u2013849","journal-title":"Br J Cancer"},{"issue":"7","key":"1235_CR18","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1200\/JCO.1992.10.7.1066","volume":"10","author":"PJ Loehrer Sr","year":"1992","unstructured":"Loehrer\u00a0PJ Sr, Einhorn\u00a0LH, Elson\u00a0PJ, Crawford\u00a0ED, Kuebler\u00a0P, Tannock\u00a0I, Raghavan\u00a0D, Stuart-Harris\u00a0R, Sarosdy\u00a0MF, Lowe\u00a0BA (1992) A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a\u00a0cooperative group study. J\u00a0Clin Oncol 10(7):1066","journal-title":"J Clin Oncol"},{"key":"1235_CR19","doi-asserted-by":"publisher","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","volume":"18","author":"H von der Maase","year":"2000","unstructured":"von der Maase\u00a0H, Hansen\u00a0SW, Roberts\u00a0JT et\u00a0al (2000) Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a\u00a0large, randomized, multinational, multicenter, phase III study. J\u00a0Clin Oncol 18:3068\u20133077","journal-title":"J Clin Oncol"},{"issue":"21","key":"1235_CR20","doi-asserted-by":"publisher","first-page":"4602","DOI":"10.1200\/JCO.2005.07.757","volume":"23","author":"H von der Maase","year":"2005","unstructured":"von der Maase\u00a0H, Sengelov\u00a0L, Roberts\u00a0JT, Ricci\u00a0S, Dogliotti\u00a0L, Oliver\u00a0T, Moore\u00a0MJ, Zimmermann\u00a0A, Arning\u00a0M (2005) Long-term survival results of a\u00a0randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J\u00a0Clin Oncol 23(21):4602\u20134608","journal-title":"J Clin Oncol"},{"issue":"12","key":"1235_CR21","doi-asserted-by":"publisher","first-page":"3018","DOI":"10.1200\/JCO.2001.19.12.3018","volume":"19","author":"AA Meluch","year":"2001","unstructured":"Meluch\u00a0AA, Greco\u00a0FA, Burris\u00a0HA 3rd, O\u2019Rourke\u00a0T, Ortega\u00a0G, Steis\u00a0RG, Morrissey\u00a0LH, Johnson\u00a0V, Hainsworth\u00a0JD (2001) Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a\u00a0phase II trial of the Minnie pearl cancer research network. J\u00a0Clin Oncol 19(12):3018","journal-title":"J Clin Oncol"},{"issue":"15","key":"1235_CR22","doi-asserted-by":"publisher","first-page":"4546","DOI":"10.1200\/JCO.2019.37.15_suppl.4546","volume":"37","author":"PH O\u2019Donnell","year":"2019","unstructured":"O\u2019Donnell\u00a0PH, Balar\u00a0AV, Vuky\u00a0J, Castellano\u00a0DE, Bellmunt\u00a0J, Powles\u00a0T, Bajorin\u00a0DF, Grivas\u00a0P, Hahn\u00a0NM, Plimack\u00a0ER, Savage\u00a0MJ, Fang\u00a0X, Godwin\u00a0JL, Frenkl\u00a0TL, de Wit\u00a0R (2019) KEYNOTE-052: phase 2 study evaluating first-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC)\u2014updated response and survival results. J\u00a0Clin Oncol 37(15):4546\u20134546","journal-title":"J Clin Oncol"},{"issue":"387","key":"1235_CR23","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","volume":"7","author":"JE Rosenberg","year":"2016","unstructured":"Rosenberg\u00a0JE et al (2016) Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 7(387):1909\u20131920","journal-title":"Lancet"},{"key":"1235_CR24","doi-asserted-by":"publisher","unstructured":"Sternberg CN, Yagoda A, Scher HI, et\u00a0al (1989) Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer 64(12):2448\u20132458. https:\/\/doi.org\/10.1002\/1097-0142(19891215)64:12<2448::aid-cncr2820641209>3.0.co;2-7","DOI":"10.1002\/1097-0142(19891215)64:12<2448::aid-cncr2820641209>3.0.co;2-7"},{"key":"1235_CR25","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1200\/JCO.2001.19.10.2638","volume":"19","author":"CN Sternberg","year":"2001","unstructured":"Sternberg\u00a0CN, de Mulder\u00a0PH, Schornagel\u00a0JH, European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group et al (2001) Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European organization for research and treatment of cancer protocol no. 30924. J\u00a0Clin Oncol 19:2638\u20132646","journal-title":"J Clin Oncol"},{"key":"1235_CR26","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.ejca.2005.08.032","volume":"42","author":"CN Sternberg","year":"2006","unstructured":"Sternberg\u00a0CN et al (2006) Seven year update of an EORTC phase III trial of high-dose intensity M\u2011VAC chemotherapy and G\u2011CSF versus classic M\u2011VAC in advanced urothelial tract tumours. Eur J Cancer 42:50","journal-title":"Eur J Cancer"}],"container-title":["Der Urologe"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-020-01235-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00120-020-01235-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-020-01235-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T23:05:28Z","timestamp":1622761528000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00120-020-01235-4"}},"subtitle":["Update Immunonkologie"],"short-title":[],"issued":{"date-parts":[[2020,6,4]]},"references-count":26,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["1235"],"URL":"https:\/\/doi.org\/10.1007\/s00120-020-01235-4","relation":{},"ISSN":["0340-2592","1433-0563"],"issn-type":[{"value":"0340-2592","type":"print"},{"value":"1433-0563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,4]]},"assertion":[{"value":"4 June 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"A.\u00a0Zacharis gibt an, dass kein Interessenkonflikt besteht. C.\u00a0Gr\u00fcllich: Beratert\u00e4tigkeit f\u00fcr BMS, ROCHE, MSD, IPSEN, EISAI, Apogepha, Pfizer, Novartis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}